GluN2C/D Subunit Selective Antagonists of the N-Methyl-D-Aspartate Receptor
US-2024294493-A1 · Sep 5, 2024 · US
Substituted pyrazoles as heat shock transcription factor activators
US9717709B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9717709-B2 |
| Application number | US-201615269584-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 19, 2016 |
| Priority date | Nov 12, 2010 |
| Publication date | Aug 1, 2017 |
| Grant date | Aug 1, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.
First claim
Opening claim text (preview).
We claim: 1. A method for modulating heat shock transcription factor activity in a human, comprising administering to a human in need thereof a therapeutically effective amount of a compound selected from the group consisting of: 2. The method of claim 1 , wherein the human suffers from a disease caused by mis-folded proteins. 3. The method of claim 1 , wherein the human suffers from a disease selected from the group consisting of Huntington's disease, Parkinson's disease, Alzheimer's disease and amyotropic lateral sclerosis.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Ophthalmic agents · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Anti-Parkinson drugs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9717709B2 cover?
- The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provide…
- Who is the assignee on this patent?
- Univ Duke, Chaperone Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4155. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).